Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health Survey

LUTS: Lower Urinary Tract Symptoms, 05/17/2012

Treatment of overactive bladder with solifenacin is associated with significant improvement in generic health–related quality of life (HRQoL) and disease–specific symptoms at 8 weeks after drug administration. Particularly for generic HRQoL as measured by the 36–Item Short Form Health Survey, solifenacin treatment effectively improves three SF–36 scores: physical function, vitality, and mental health.

Print Article Summary Cat 2 CME Report